A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 28 Apr 2025
At a glance
- Drugs ANS 014004 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 04 Oct 2024 According to Beijing Advaccine Biotechnology Media Release, company announced that this trial was recently cleared to proceed with enrollment of patients in Canada by Health Canada.
- 26 Jul 2024 Status changed from not yet recruiting to recruiting.
- 11 Mar 2024 Status changed from planning to not yet recruiting.